Core Insights - The company is excited about the recent Phase II data readout, which is significant for patients and indicates a positive outcome for their treatment approach [1][2]. Company Overview - The CEO expressed gratitude for the opportunity to present the company's story and recent data, highlighting the importance of the findings [2]. Market Context - The market for the company's treatment is substantial, with approximately 1.8 million patients in the U.S. affected, of which around 40% (approximately 560,000 patients) are treatment-resistant [3].